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Vastus Lateralis Fiber Shift Is an
Independent Predictor of Mortality in
Chronic Obstructive Pulmonary Disease
To the Editor:
Quadriceps weakness and atrophy is present in approximately
30% of patients with chronic obstructive pulmonary disease
(COPD) in secondary care (1, 2). The quadriceps also displays
a shift in ﬁber type so that there are fewer type I (oxidative)
ﬁbers and more type II (glycolytic) ﬁbers (3). Pulmonary
rehabilitation only partially addresses this ﬁber shift (4). Muscle
mass (5) and strength (6) are both associated with increased
mortality, but the prognostic signiﬁcance of ﬁber shift is
unknown.
In a retrospective multicenter analysis of 392 patients from
four sites (see Tables E1–E4 in the online supplement), mortality
data were collated, as part of audit procedures, on outpatients
with stable COPD who had undergone a vastus lateralis biopsy
between 1995 and 2013. Data from these subjects have been
previously published (e.g., References 2, 4, 5). Fiber proportion,
reported as the percentage of type II ﬁbers (type II ﬁber %), was
established by immunohistochemistry. Fiber shift, evaluated as
a dichotomous variable, was considered to have occurred when
the proportion of type II ﬁbers was greater than 68% (men) or
greater than 65% (women) based on normal ranges established
from an age-matched healthy population published by Natanek
and colleagues (3). Body mass index (BMI), fat-free mass index
(FFMI), dominant leg isometric quadriceps maximum voluntary
contraction (QMVC and QMVC/BMI), mid-thigh cross-sectional
area determined by computed tomography scan (MTCSA),
residual volume normalized to total lung capacity (RV/TLC),
and percent predicted value for the carbon monoxide transfer
factor corrected for hemoglobin (TLCOc), when available, were
included in subanalyses. Data were analyzed for the whole dataset
and also after splitting the group into those with an FEV1 less
than 50% predicted and those with an FEV1 greater than or equal
to 50% predicted. Further details on the methodology and
statistical analyses are presented in the online supplement. Some
of the results of this study have been previously reported in
abstract form (7).
Patients were followed up for a median of 1,699 days
(127–6,601 d); 102 of 392 (26.7%) patients died during follow-
up (Table E6). Cohort characteristics are presented in Tables 1
and 2 and Tables E1–E5. One hundred ﬁfty-one patients
had Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stage I/II disease and 241 had GOLD stage III/IV
disease. Those who died were older and had a lower FEV1 %
predicted, and there was a greater male preponderance
(Table E6A). One hundred seventy-seven (45.1%) of the
patients had ﬁber shift. The patients who died had a higher
percentage of type II ﬁbers (69.5% [62.2, 76.3%] vs. 66.0%
[54.0, 74.2%]; P = 0.002) and a higher proportion of them
exhibited ﬁber shift (58% vs. 41%, P = 0.004). BMI, FFMI,
QMVC, MTCSA, and TLCOc were all lower, and RV/TLC
higher, in those who died (Table E6B).
In the cohort considered as a whole, both type II ﬁber % and
the presence of ﬁber shift were univariate predictors of mortality,
as were age and FEV1 % predicted (Tables 1 and 2). In a
multivariate analysis including ﬁber shift as a dichotomous
variable, ﬁber shift was retained, as were age and FEV1 %
predicted, Table 1. When age, FEV1 % predicted, and type II
ﬁber % were entered into a multivariate analysis, age and
FEV1 % predicted were retained as independent predictors, but
the association between ﬁber type and mortality just missed
statistical signiﬁcance (Table 2). The relationship between FEV1
and ﬁber proportion is shown in Figure 1A, and survival as a
function of ﬁber shift, adjusted for age and FEV1, is shown
in Figure 1B. Additional data regarding other lung function and
muscle parameters are presented in Tables E7–E10. FEV1
expressed in liters and TLCOc were also univariate predictors of
mortality; however, RV/TLC was not. When including TLCOc
in the analysis (n = 209), ﬁber shift, age, FEV1 % predicted, and
TLCOc were all independent predictors of mortality. In other
subanalyses, BMI, FFMI, QMVC, QMVC/BMI, and MTCSA
were not univariate predictors of mortality.
When limiting the analysis to those with an FEV1 greater
than or equal to 50% predicted, age was the only predictor of
mortality (hazard ratio [HR], 1.16; 95% CI, 1.07, 1.25; P ,
0.0001; Table E11). In a multivariate analysis conﬁned to those
with an FEV1 less than 50%, ﬁber shift was retained as an
independent predictor (HR, 1.71; 95% CI, 1.08, 2.71; P = 0.02), as
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were age (HR, 1.06; 95% CI, 1.03, 1.09; P , 0.0001), and FEV1 %
predicted (HR, 0.96; 95% CI, 0.94, 0.99; P = 0.002; Table E12A).
In a separate analysis conﬁned to those with an FEV1 less than
50%, type II ﬁber % was not retained as an independent predictor
(HR, 1.014; 95% CI, 0.996, 1.032; P = 0.13), whereas age and FEV1
% predicted were (Table E12B).
Fiber shift in the vastus lateralis of patients with COPD
was associated with increased mortality, although this association
was weaker when lung function and age were included in
the analysis. This ﬁnding was pronounced in patients with GOLD
stage III/IV disease but undetectable in those with GOLD stage I/II
disease. The relationship between skeletal muscle atrophy (5)
and weakness (6) with mortality has been previously noted in
COPD. However, we believe the present analysis is timely because
we (3) and others (8) have recently shown that the nature of
skeletal muscle involvement in COPD is heterogeneous rather than
uniform. No prior study has related quadriceps biopsy appearances
to long-term outcome in COPD.
Given the known relationship between exercise capacity and
survival (9), these data are consistent with our prior studies,
which demonstrated a relationship between ﬁber shift (although
not ﬁber atrophy) and impaired exercise capacity (3) and
functional performance (10). Nevertheless, it remains unclear
whether ﬁber shift causes poor exercise tolerance or is
a manifestation of exercise intolerance and reduced physical
activity, which are both associated with increased mortality in
COPD (9, 11). Both concepts can be supported by in vivo models
that demonstrate that muscle disuse results in type I to type II
ﬁber shift (12) and that ﬁber shift toward a type I ﬁber
predominance increases exercise performance (13). Due to the
retrospective nature of the current analysis, exercise performance
and physical activity data were not available for inclusion in this
report, so a causative role for ﬁber shift in mortality cannot be
demonstrated from this study. A prospective study would have
been preferable and could also have considered other factors
of relevance, including pulmonary rehabilitation over the
intervening period. Despite the limitations of the current study,
it is doubtful that a prospective study of comparable size and
duration will ever be done.
Interest in pharmacological management of skeletal muscle
dysfunction is growing (14), and addressing ﬁber shift may eventually
become a therapeutic possibility. Further studies to address whether
the reversal of ﬁber shift is of beneﬁt are of value. n
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Table 2. Core Characteristics of the Cohort (n = 392) in Addition to Univariate and Multivariate Analyses Including Type II Fiber
Proportion as a Continuous Measure
Parameter %/Mean (SD)/Median (IQR) Univariate HR (95% CI) P Value Multivariate HR (95% CI) P Value
Age, yr 65.9 (8) 1.045 (1.018, 1.072) 0.001 1.072 (1.041, 1.103) ,0.0001
Male sex, % 73 1.346 (0.805, 2.252) 0.257 — —
FEV1 % predicted 41.6 (28.0, 61.0) 0.970 (0.957, 0.982) ,0.0001 0.965 (0.951, 0.979) ,0.0001
% Type II ﬁbers 66.6 (56.0, 75.0) 1.024 (1.009, 1.039) 0.002 1.014 (0.998, 1.030) 0.088
Definition of abbreviations: CI = confidence interval; HR = hazard ratio; IQR = interquartile range.
Table 1. Core Characteristics of the Cohort (n = 392) in Addition to Univariate and Multivariate Analyses Including Type II Fiber
Proportion Dichotomized into the Occurrence of Fiber Shift
Parameter %/Mean (SD)/Median (IQR) Univariate HR (95% CI) P Value Multivariate HR (95% CI) P Value
Age, yr 65.9 (8) 1.045 (1.018, 1.072) 0.001 1.070 (1.040, 1.101) ,0.0001
Male sex, % 73 1.346 (0.805, 2.252) 0.257 — —
FEV1 % predicted 41.6 (28.0, 61.0) 0.970 (0.957, 0.982) ,0.0001 0.965 (0.951, 0.979) ,0.0001
Fiber shift present 45 2.073 (1.390, 3.091) 0.001 1.598 (1.056, 2.419) 0.027
Definition of abbreviations: CI = confidence interval; HR = hazard ratio; IQR = interquartile range.
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Spirometry in the Occupational Setting
To the Editor:
We read with great interest the recent American Thoracic Society
(ATS) recommendations for performance of spirometry in the
workplace (1). The ﬁrst question addressed in the guideline, and
about which a recommendation is made, concerns the importance
of technologist training as a key component for obtaining good
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Figure 1. (A) The relationship between type II fiber percentage and FEV1 % predicted (dashed lines demonstrate the 95% confidence interval), and (B)
survival curves for those with fiber shift (n = 177) and those without fiber shift (n = 215) after adjusting for age and FEV1 % predicted as covariates.
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